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Abstract
Purpose: Vascular endothelial growth factor-A (VEGF-A) is one of the most important factors inducing angio-
genesis in tumors. Nine splice-variant isoforms of VEGF-A have been identified, each having different properties.
Recently, we showed that radiolabeled anti-VEGFmonoclonal antibody, bevacizumab, accumulates specifically in
VEGF-A expressing tumors. In this study, we investigated in a nude mouse model which VEGF-isoforms are
responsible for tumor accretion.
Materials and Methods: The humanized anti-VEGF-A antibody, A.4.6.1. (bevacizumab), was radiolabeled with
In-111. The originally VEGF-negative Mel57 tumor was transfected with different VEGF isoforms (VEGF-121,
VEGF-165, and VEGF-189). The obtained melanoma xenografts specifically expressing different VEGF-isoforms
were used in mice. The bevacizumab uptake was examined in biodistribution studies and by gamma-camera
imaging.
Results: The tumor cell line expressing VEGF-121 did not show specific uptake, most likely as a result of the fact
that this isoform is freely diffusible. Tumors expressing VEGF-165 and -189 were clearly visualized by using
gamma-camera imaging.
Conclusion: The accumulation of radiolabeled bevacizumab in the tumor is due to interaction with VEGF-A
isoforms that are associated with the tumor cell surface and=or the extracellular matrix. Scintigraphic imaging of
the expression of these VEGF isoforms may thus be useful to predict response to angiogenic therapy.
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Introduction
Tumors cannot grow beyond a size of 1–2mm
3 unless
new blood vessels are formed for oxygen and nutrient
supply.1 Angiogenesis is a complex process that is regulated
by the actions of prol and antiangiogenic cytokines and hor-
mones. Vascular endothelial growth factor-A (VEGF-A) is one
of the most important proangiogenic growth factors. A well-
characterized activity of VEGF-A is its ability to promote the
growth and migration of vascular endothelial cells derived
from arteries, veins, and even lymphatics.2 VEGF-A is the
best-characterizedmember of the VEGF family and is thought
to be the predominant and most critical regulator of the de-
velopment of the vascular system in various tumors.3
The human VEGF-A gene is organized in nine exons,
separated by eight introns4 and is localized on chromosome
6p21.3.5 Alternative splicing may result in the generation of
six isoforms, having 121, 145, 165, 183, 189, and 206 amino
acids, respectively, after signal-sequence cleavage. The amino
acids encoded by exons 1–5 and 8 are contained in all iso-
forms. Exons 6 and 7 encode heparin-binding domains, which
influence receptor binding and solubility. VEGF-189 and
-206 contain a domain encoded by exon 6 and bind to hepa-
rin and heparan sulphate proteoglycans (HSPGs) with high
affinity and are almost completely sequestered in the extra-
cellular matrix (ECM). VEGF-165 is the most predominant
isoform6: It contains the exon 7–encoded domain, but lacks
exon 6 and has intermediate properties; it is secreted, but a
significant portion is bound to HSPGs on the cell surface and
ECM.7 VEGF-121, which lacks both exons 6 and 7, does not
bind to heparin and HSPGs and is, consequently, freely dif-
fusible.8 We previously demonstrated, in a brain metastases
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model, that VEGF-165 and -189 are angiogenic, whereas
VEGF-121 mainly induced vasodilatation and vascular per-
meability. In clinical tumors, the 121 and 165 isoforms, and to
a lesser extent, VEGF-A189, are the predominant VEGF iso-
forms.9,10
Bevacizumab is a humanized variant of the anti-VEGF-A
monoclonal antibody (mAb), A.4.6.1. It is directed aginst a
common epitope encoded by exon 4 and expressed on all
VEGF-A isoforms, preventing interaction with the tyrosine
kinase receptors, VEGFR-1 and -2.11 It has been shown that
antiangiogenic properties of bevacizumab result in growth
inhibition of human tumors in nudemice.12 Bevacizumabwas
the first Food and Drug Administration–approved clinical
agent to target tumor angiogenesis and has been registered in
February 2004 for the first-line treatment of metastatic colo-
rectal cancer in combination with Fluorouracel (5-FU)-based
chemotherapy.13 In a recent trial, the addition of bevacizumab
to standard chemotherapy also produced a significant sur-
vival benefit in patients with advanced metastatic non-small-
cell lung cancer,14 and it was approved for initial treatment of
irresectable non-small-cell lung cancer in combination with
carboplatin and paclitaxel in October 2006.
The marked variation in functional anatomy and patho-
physiology within human tumors and within individual
patients may account for the high variability of responses
observed in patients.15 For example, in vessel-dense tissues
such as the liver, tumors may profit from preexistent vas-
culature, thereby reducing the dependency on angiogenesis.
Liver metastases from colorectal adenocarcinomas grow in
three patterns with different angiogenesis and desmoplasia,
as pointed out by Vermeulen et al.16 As a result, there is an
urgent need for reliable markers that can predict which pa-
tients are most likely to respond to anti-VEGF therapy.
In a previous study, we showed that VEGF-A expression
by the LS174T colon tumor xenografts could be visualized by
gamma-camera imaging after the intravenous (i.v.) injection
of In-111-labeled anti-VEGF mAb.17,18 VEGF-A expression in
these xenografts was limited to the 121 and 165 amino-acid
variants. However, it remains unclear which isoform(s) were
visualized in these imaging experiments. The aim of this
study was to determine which VEGF isoforms were actually
targeted. Therefore, we analyzed bevacizumab uptake in
melanoma xenografts in nude mice selectively expressing
VEGF-121, -165, or -189.
Materials and Methods
Tumor model
All animal experiments were approved by the Animal
Experiments Committee of the Radboud University Nijme-
gen Medical Center (Nijmegen, The Netherlands) and per-
formed in accordance with their guidelines. Male nude
BALB=c mice, 6–8 weeks old, were used after an acclimati-
zation period of 2 weeks. The mice were housed (4 per cage)
in a controlled environment with light-dark cycle conditions
(12 hour light and 12 h dark) and had free access to water
and food. Stable transfectants of the Mel57 human melanoma
cell line expressing VEGF-121, -165, or -189 were obtained, as
described previously.19 Expression of proteins of the appro-
priate size in conditioned medium was confirmed by using
Western blot, using anti-VEGF antibody A20 (Santa Cruz
Biotechnology, Santa Cruz, CA).
Radiolabeling and quality control
For labeling with In-111, bevacizumab was conjugated
with isothiocyanato-benzyl-DTPA (diethylene triamine pen-
teacetic acid), as described previously.20 Bevacizumab-DTPA
(50 mg) was incubated with 20MBq of In-111 in 0.15M
of ammonium acetate buffer (pH 5.5) for 30minutes. The
radiolabeled antibody preparations were purified by gel fil-
tration on a PD-10 column (Amersham Biosciences, Roo-
sendaal, The Netherlands) eluted with phosphate buffered
saline (PBS) in 0.5% bovine serum calbumin (BSA). The ra-
diochemical purity (RCP) of the radiolabeled mAb (specific
activity 0.3MBq=mg) was determined by instant thin-layer
chromatography (ITLC) and exceeded 97% for all prepara-
tions used in the studies.
VEGF-A levels in tumor xenografts
From the frozen melanoma xenografts expressing the
different VEGF isoforms (VEGF-121, -165, and -189), thick
cryosections were cut and pooled in RIPA buffer, (150mM of
NaCl, 10mM of Tris-HCl, pH 7.4, 1mM of ethylene diamine
tetraacetic acid, 1% NP-40, and 0.5% sodiumdeoxycholate)
and a protease inhibitors cocktail (Roche, Basel, Switzerland)
containing heparin (5U=mL) to release matrix-bound iso-
forms of VEGF-A. Sections were homogenized, incubated
on ice for 20 minutes, and centrifuged (800g, for 20 minutes at
48C) to prepare a clear lysate. Protein concentrations were
determined by the Bradford method (Biorad, Hercules, CA),
andVEGF-A concentrationsweremeasured by enzyme linked
immunosorbent assay (ELISA) as described previously.21 This
ELISA detects all VEGF-isoforms.
Biodistribution and imaging experiments
Nude mice were injected subcutaneously (s.c.) in the left
flank with 0.2mL of Matrigel (Becton Dickinson, Franklin
Lakes, NJ) containing 4105 Mel57-wt, Mel57-VEGF-121,
Mel57-VEGF-165, or Mel57-VEGF-189 cells (n¼ 8 for each
group). Approximately 14 days later, mice bearing 2–3mm-
diameter tumors (approximately 0.1 g) received an i.v. injec-
tion (via the tail vein) of 0.2MBq of In-111-bevacizumab
(0.2mL). Three (3) mice from each groupwere coinjected with
an excess of unlabeled bevacizumab (300mg). Three (3) days
after injection, mice were killed by CO2=O2 asphyxiation and
tissues (blood, muscle, lung, spleen, kidney, liver, and small
intestine) were dissected and weighed. The radioactivity in
the tissues was measured in a gamma-counter (Wizard;
Pharmacia-LKB Uppsala, Sweden). Injection standards were
counted simultaneously for correction of decay. The activity
concentration in the samples was calculated and expressed as
percent injected dose (%ID=g) of tissue.
Scintigraphic imaging
For imaging experiments, mice with 3–6mm-diameter s.c.
Mel57 tumors expressing the different isoforms (n¼ 3 in each
group) were i.v. injected with 1MBq of In-111-bevacizumab
(in 0.2mL). Scintigraphic images were acquired immediately
and at 1, 3, and 7 days postinjection. For imaging, mice were
anesthetized by isoflurane=N2O=O2 inhalation anesthesia and
placed prone on a single-head gamma camera (Orbitor; Sie-
mens, Hoffman Estates, IL) equipped with a parallel-hole
medium-energy collimator. Images (100,000 counts=image)
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were stored digitally in a 256256 matrix. After the acqui-
sition of the last images, mice were killed and tumors were
snap-frozen for further analysis.
Results
VEGF-A levels in tumor xenografts
VEGF-A levels in tumor tissue extract were determined by
using an ELISA assay. VEGF levels in the tumor extracts
varied from 0.24 mg=g per tumor in the Mel57-wt xenograft
to 4.03 mg=g per tumor in the Mel57-VEGF-165 xenograft.
The VEGF levels in the Mel57-VEGF-121 and Mel57-VEGF-
189 xenograft amounted to 0.64 and 1.13 mg=g per tumor,
respectively. We found no correlation between the VEGF
levels in the tumor xenografts and the specific accumulation
of radiolabeled bevacizumab (Spearman correlation, 0.8;
p< 0.20).
Biodistribution experiment
Expression of VEGF-A isoforms by the respective Mel57
transfectants is shown in Figure 1. The different transfectants
exclusively produce the transfected isoform. The biodistri-
bution of In-111-bevacizumab in mice with s.c. Mel57 tumors
expressing different VEGF-A isoforms is summarized in Fig-
ure 2A–2D.Mel57wild-type xenografts, known to express low
levels of VEGF-A,22 showed an In-111-bevacizumab concen-
tration of 8.6 1.2 %ID=g. In the presence of an excess of un-
labeled bevacizumab, the tumor uptake of the In-111-labeled
antibody was reduced significantly: 3.9 0.34 %ID=g, indi-
cating that half of the antibody uptake was VEGF mediated.
The concentration of In-111-bevacizumab in theMel57-VEGF-
121 tumor was 20 3 %ID=g. Uptake in the Mel57-VEGF-121
tumors and normal tissues was not reduced in the pres-
ence of 300 mg of unlabeled antibody, indicating that In-111-
bevacizumab accumulated only nonspecifically in these
tumors. The concentration of In-111-bevacizumab in the
Mel57-VEGF-189 tumor was 37 13 %ID=g. Mel57-VEGF-
165 tumors demonstrated an extremely high bevacizumab
uptake of 64 12 %ID=g, resulting in a tumor-to-blood ratio
as high as 7.9 at 3 days postinjection. The concentration
of In-111-bevacizumab in the Mel57-VEGF-165 and Mel57-
VEGF-189 tumors decreased significantly upon the coinjec-
tion of an excess unlabeled antibody (20 and 4 %ID=g re-
spectively), indicating that the major part of bevacizumab
uptake in these tumors was specific (VEGF mediated).
Scintigraphic imaging
The images acquired at several time points after injection
are shown in Figure 3. Immediately after injection (day 0),
radioactivity was mainly present in the heart region and well-
perfused organs. At day 3 post injection, activity had accu-
mulated in the VEGF-165- and -189-positive tumors and had
cleared from the circulation and nontarget organs, resulting in
the distinct visualization of these tumors. Image quality fur-
ther improved at day 7. The Mel57 wild-type tumors and the
Mel57 tumors expressing VEGF-121 were not delineated in
the images acquired 3 and 7 days postinjection, confirming the
lack of specific accumulation of the antibody in these tumors.
Discussion
We and others recently demonstrated that radiolabeled
bevacizumab specifically accumulates in VEGF-A expressing
tumors xenografted in nude mice.17,23 The In-111-labeled an-
tibody allowed the detection of VEGF-A expression non-
invasively by scintigraphic imaging. Bevacizumab is reported
to have a high affinity for all VEGF-A isoforms, but it was
unclear which isoforms expressed in the tumor were actually
targeted and caused the specific accumulation in the tumor.
Because previous work has shown that the larger isoforms of
VEGF-A are more potent inducers of angiogenesis,9 it is im-
portant to know which VEGF-A isoform(s) are visualized
during anti-VEGF imaging.
To determine which of the isoforms are responsible for
the specific bevacizumab uptake, we used stable transfec-
tants of the human melanoma cell line, Mel57, expressing
each isoform in vitro at levels of 30–100 ng=mL per 106 cells
in 48 hours.9 The parental Mel57 cell line produces min-
imal amounts of VEGF-A in vitro.22 Consequently, Mel57
xenografts in nude mice grow to necrotic tumors, whereas
VEGF-A-165 expression by these tumors results in a highly
vascularized phenotype.24 In the present study, we demon-
strate that only expression of the cell- or matrix-associated
VEGF-A isoforms (VEGF-165 and -189) resulted in the tumor
accumulation of radiolabeled bevacizumab.
The low levels of VEGF-A produced by the parental Mel57
xenografts were reflected in a very low specific uptake of
bevacizumab. Specificity was assessed by the coinjection of an
excess of unlabeled antibody. Highest tumor uptake was ob-
served in the Mel57 tumor expressing VEGF-A-165 (64 12
%ID=g). The Mel57-VEGF-189 tumor also showed a high and
specific tumor uptake. This high antibody uptake most likely
is due to the properties of VEGF-165 and -189: A significant
portion remains bound to the cell surface and the extracellular
FIG. 1. Expression of vascular endothelial growth factor
(VEGF) isoforms by Mel57 transfectants in vitro. A Western
blot is shown containing conditioned medium of Mel57 (lane
1), Mel57-VEGF-A121 (lane 2), Mel57-VEGF-A165 (lane 3),
and Mel57-VEGF-A189 (lane 4). Note the absence of VEGF in
parental Mel57 cells. Every isoform is secreted as a glyco-
sylated protein, resulting in the doublet character.
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matrix. Interestingly, uptake in the Mel57-VEGF-121 tumors
was not reduced when an excess of unlabeled antibody was
coinjected, indicating that the antibody localized in these
tumors nonspecifically. This can be explained by the fact
that VEGF-121 is not retained in these tumors, resulting in
the formation of soluble VEGF-antibody immune complexes
that are not retained in the tumor.
In this study, major differences in nonspecific uptake of
bevacizumab in the Mel57 variants were observed. The
concentration of radiolabeled bevacizumab, when coinject-
ing an excess dose of unlabeled antibody, was relatively high
in the tumors expressing the VEGF-isoforms, 121 and 165:
17.4 2.23 and 19.6 3.01 %ID=g, respectively. This may be
the result of differences in blood volume, vascular perme-
ability, and=or interstitial fluid pressure in the tumor xeno-
grafts, as VEGF-121 is reported to induce vasodilatation and
to enhance vascular permeability. When grown in a brain
metastasis model, Mel57 tumors that exclusively express
VEGF-121 are characterized by a relative absence of intra-
tumoral blood vessels, whereas highly dilated and hyper-
permeable supposedly preexistent vessels are present in a
peritumoral rim. VEGF-165 and -189 induce the formation of
an intratumoral neovascular bed, consisting of irregularly
dilated and leaky vessels. This is more prominent in VEGF-
165-expressing tumors, when compared with VEGF-189 tu-
mors.9 Thus, the enhanced nonspecific localization in the
VEGF-121 and -165 tumors may be due to enhanced vascular
permeability, which may cause enhanced extravasation of
bevacizumab in this tumor. However, further studies are
needed to make proof of this assumption. Such an experi-
ment should measure the vascular permeability of the tumor
xenograft transfected with VEGF-121.
The localization of radiolabeled bevacizumab in mice
bearing s.c. xenografted human tumors expressing particu-
lar VEGF isoforms was also studied by scintigraphic imag-
ing. The tumors expressing VEGF-165 and -189 were clearly
visualized, whereas the tumors expressing the VEGF-121
isoform could not be delineated. VEGF-165 and -189 are ex-
tracellular matrix–bound proteins and are known to be most
capable of inducing angiogenesis. Imaging these VEGF iso-
forms may, therefore, be useful in selecting patients who are
likely to respond to antiangiogenic therapy.
However, part of the response to antiangiogenic therapy
could be due to reducing the interstitial fluid pressure in the
tumor. VEGF-121 may not be the main isoform responsible
for angiogenesis, but this isoform is well capable of inducing
vasodilatation and enhancing vascular permeability. This
results in inefficient blood flow and high interstitial fluid
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FIG. 2. Biodistribution of In-111-bevacizumab in athymic male mice with subcutaneous Mel57 tumors at 3 days postin-
jection (8 mice per group, with 3 of each group coinjected with an excess of 300mg of unlabeled bevacizumab) (A) Mel57-wt;
(B) Mel57-VEGF-121; (C) Mel57-VEGF-165; and (D) Mel57-VEGF-189. VEGF, vascular endothelial growth factor.
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pressure in the tumor, which leads to decreased uptake
of drugs or other therapeutics in tumors. Combining anti-
VEGF-therapy with chemotherapy has resulted in an anti-
tumor effect, presumably by the normalization of the tumor
vasculature, partly as a result of blocking the effect of
VEGF-121. As described above, the tumors expressing the
VEGF-121 isoform could not be delineated.
Conclusions
This study is the first to demonstrate the specific tumor
localization of radiolabeled bevacizumab in xenografted
human tumors expressing particular VEGF isoforms. Tu-
mors expressing only VEGF-121 showed no specific uptake
of radiolabeled bevacizumab, most likely as a result of the
fact that this isoform is freely diffusible and is not retained in
the tumor. Mel57-VEGF-165 and Mel57-VEGF-189 demon-
strated relatively high, specific tumor uptake of the labeled
antibody. Thus, scintigraphy with radiolabeled bevacizumab
appears to allow in vivo visualization of the VEGF-A iso-
forms that are most capable of inducing angiogenesis and
may thus be useful to predict response to antiangiogenic
therapy. However, it should be noted that tumors with
predominantly VEGF-121 expression will not be visualized,
whereas such tumors might still be susceptible to avastin-
induced vessel normalization.
FIG. 3. Scintigraphic images of athymic male mice with subcutaneous Mel57 tumors expressing different VEGF isoforms
immediately after injection and at 1, 3, and 7 days postinjection of In-111-bevacizumab (1MBq=mouse, 3 mg=mouse). VEGF,
vascular endothelial growth factor.
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